Advertisement

ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients

  • Yasmeen Razvi
  • Stephanie Chan
  • Thomas McFarlane
  • Erin McKenzie
  • Pearl Zaki
  • Carlo DeAngelis
  • William Pidduck
  • Ahmad Bushehri
  • Edward Chow
  • Katarzyna Joanna Jerzak
Review Article

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with a variety of early- and end-stage malignancies. In light of recent changes in the optimal management of CINV, we undertook this narrative review to compare the latest guidelines published by ASCO (2017), NCCN (2018), and MASCC/ESMO (2016). The processes undertaken by each organization to evaluate existing literature were also described. Although ASCO, NCCN, and MASCC/ESMO guidelines for the treatment and prevention of CINV share many fundamental similarities, literature surrounding low and minimal emetic risk regimens is lacking. Data regarding the use of complementary alternative medicine for CINV is particularly scarce and in need of further investigation.

Keywords

Guidelines Chemotherapy-induced nausea and vomiting Prophylaxis Antiemetic 

Notes

Acknowledgements

We thank the generous support of Bratty Family Fund, Michael and Karyn Goldstein Cancer Research Fund, Joey and Mary Furfari Cancer Research Fund, Pulenzas Cancer Research Fund, Joseph and Silvana Melara Cancer Research Fund, and Ofelia Cancer Research Fund.

Compliance with ethical standards

Conflict of interest

TM attended an advisory board for Purdue Pharma. EC attended an advisory board for Purdue Pharma and served as a moderator for a Purdue Pharma dinner seminar. KJJ served as a consultant for and/or attended advisory boards for Genomic Health Inc, Novartis, Purdue Pharma and Roche.

References

  1. 1.
    Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MHN (1983) On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208CrossRefGoogle Scholar
  2. 2.
    Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MHN (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol Off J Eur Soc Med Oncol 7:189–195CrossRefGoogle Scholar
  3. 3.
    Kuchuk I, Bouganim N, Beusterien K et al (2013) Patient perceptions about potential side effects and benefits from chemotherapy agents. J Clin Oncol 31:6595–6595.  https://doi.org/10.1200/JCO.2013.31.15_SUPPL.6595 CrossRefGoogle Scholar
  4. 4.
    Matzka M, Köck-Hódi S, Jahn P, Mayer H (2018) Relationship among symptom clusters, quality of life, and treatment-specific optimism in patients with cancer. Support Care Cancer 26:1–9.  https://doi.org/10.1007/s00520-018-4102-8 CrossRefGoogle Scholar
  5. 5.
    Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13:80–84.  https://doi.org/10.1007/s00520-004-0718-y CrossRefPubMedGoogle Scholar
  6. 6.
    Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR (2005) 5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6:765–772.  https://doi.org/10.1016/S1470-2045(05)70325-9 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Navari RM (2015) Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int 2015:1–6.  https://doi.org/10.1155/2015/595894 CrossRefGoogle Scholar
  8. 8.
    Escobar Y, Cajaraville G, Virizuela JA, Álvarez R, Muñoz A, Olariaga O, Tamés MJ, Muros B, Lecumberri MJ, Feliu J, Martínez P, Adansa JC, Martínez MJ, López R, Blasco A, Gascón P, Calvo V, Luna P, Montalar J, del Barrio P, Tornamira MV (2015) Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer 23:2833–2840.  https://doi.org/10.1007/s00520-015-2809-3 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tamura K, Aiba K, Saeki T et al (2017) Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol 22:405–412.  https://doi.org/10.1007/s10147-016-1069-7 CrossRefPubMedGoogle Scholar
  10. 10.
    Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663.  https://doi.org/10.1007/s00520-012-1710-6 CrossRefPubMedGoogle Scholar
  11. 11.
    Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261.  https://doi.org/10.1200/JCO.2017.74.4789 CrossRefPubMedGoogle Scholar
  12. 12.
    Ettinger DS, Berger MJ, Aston J, et al (2018) NCCN clinical practice guidelines in oncology antiemesis version 3.2018. Natl Compr Cancer Care Netw Google Scholar
  13. 13.
    Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119–v133.  https://doi.org/10.1093/annonc/mdw270 CrossRefPubMedGoogle Scholar
  14. 14.
    Ettinger DS, Berger MJ, Aston J, et al (2017) NCCN clinical practice guidelines in oncology antiemesis version 2.2017. Natl Compr Cancer Care Netw Google Scholar
  15. 15.
    Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134–142.  https://doi.org/10.1056/NEJMoa1515725 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hashimoto H, Yanai T, Nagashima K, Tsuda N, Horinouchi H, Tomomi T (2016) A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin [abstract]. J Clin Oncol 34:10111CrossRefGoogle Scholar
  17. 17.
    Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333.  https://doi.org/10.1093/annonc/mdu101 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830.  https://doi.org/10.1200/JCO.2005.09.050 CrossRefPubMedGoogle Scholar
  19. 19.
    Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M (2014) Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol 32:101–106.  https://doi.org/10.1200/JCO.2013.51.4547 CrossRefPubMedGoogle Scholar
  20. 20.
    Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011–1015.  https://doi.org/10.1038/sj.bjc.6603048 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F, on behalf of the Italian Group for Antiemetic Research (2015) Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol 26:1248–1253.  https://doi.org/10.1093/annonc/mdv132 CrossRefPubMedGoogle Scholar
  22. 22.
    Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S, Powers D, Aapro M (2016) Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 122:2418–2425.  https://doi.org/10.1002/cncr.30054 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 27:172–178.  https://doi.org/10.1093/annonc/mdv482 CrossRefPubMedGoogle Scholar
  24. 24.
    Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, Hasuo Y, Nishida M, Masuda S, Kato K (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21:491–497.  https://doi.org/10.1007/s10147-015-0928-y CrossRefPubMedGoogle Scholar
  25. 25.
    Keat CH, Phua G, Abdul Kassim MS, Poh WK, Sriraman M (2013) Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy? Asian Pac J Cancer Prev 14:469–473CrossRefGoogle Scholar
  26. 26.
    Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20:141–147.  https://doi.org/10.1007/s00520-010-1079-3 CrossRefPubMedGoogle Scholar
  27. 27.
    Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J, Haislip ST, Perry T, Boozan TL, Meador K, Cao X, Burke TA (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 10:68–74.  https://doi.org/10.1200/JOP.2012.000816 CrossRefPubMedGoogle Scholar
  28. 28.
    Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21:1373–1378.  https://doi.org/10.1200/JCO.2003.08.118 CrossRefPubMedGoogle Scholar
  29. 29.
    Bruce K, Hall L, Castelo S, Evans M, Frangoul H (2012) Direct provider feedback to decrease chemotherapy ordering errors: the “gray envelope” initiative. Pediatr Blood Cancer 59:1330–1331.  https://doi.org/10.1002/pbc.24224 CrossRefPubMedGoogle Scholar
  30. 30.
    Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev:CD009464. doi: https://doi.org/10.1002/14651858.CD009464.pub2
  31. 31.
    Rithirangsriroj K, Manchana T, Akkayagorn L (2015) Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients. Gynecol Oncol 136:82–86.  https://doi.org/10.1016/j.ygyno.2014.10.025 CrossRefPubMedGoogle Scholar
  32. 32.
    Pergam SA, Woodfield MC, Lee CM, Cheng GS, Baker KK, Marquis SR, Fann JR (2017) Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 123(22):4488–4497.  https://doi.org/10.1002/cncr.30879 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kelly BF, Nappe TM (2018) Toxicity, CannabinoidsGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yasmeen Razvi
    • 1
  • Stephanie Chan
    • 1
  • Thomas McFarlane
    • 1
  • Erin McKenzie
    • 1
  • Pearl Zaki
    • 1
  • Carlo DeAngelis
    • 1
  • William Pidduck
    • 1
  • Ahmad Bushehri
    • 1
  • Edward Chow
    • 1
  • Katarzyna Joanna Jerzak
    • 1
    • 2
  1. 1.Sunnybrook Odette Cancer CentreUniversity of TorontoTorontoCanada
  2. 2.Department of Medical Oncology, Odette Cancer CentreSunnybrook Health Sciences CentreTorontoCanada

Personalised recommendations